Search Results

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq:

July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics

biggest opportunities will emerge: Building receptor-specific delivery systems for gene or peptide therapeutics

Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve genomic and transcriptomic profiles of ORs in glioma, we suggest that ORs are potential biomarkers and therapeutic

  ·  OMass Therapeutics  ·  Superluminal Medicines  ·  Tectonic Therapeutics  ·  and many more. , and Abilita Therapeutics. Translational Stories & Clinical Data OMass Therapeutics on long-residence MC2R antagonists. Tectonic Therapeutics on engineering a long-acting relaxin for pulmonary hypertension. Kainova Therapeutics presenting Phase 1 outcomes for their EP4 receptor antagonist in solid tumors.

June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd

Strong GPCR drug discovery decisions are built on structure, early risk awareness, and focused signal detection. If you work in GPCR research, clarity is leverage. The ability to access the right framework, detect risk early, and act on emerging signals determines whether programs accelerate—or stall. This week’s issue focuses on structure, early safety strategy, and the next wave of signal transduction research. Each piece is designed to help you make better decisions—faster. 🔍 This Week in Premium: Sneak Peek Industry insights: Confo nominates SSTR5 agonist antibody CFTX-2034; Lilly oral GLP-1 maintenance data; Enveda IND clearance ENV-308; Zealand explores brain-directed obesity therapies. Upcoming events: 12th Adhesion GPCR Workshop; GPCRnet International Symposium; 5th GPCRs Targeted Drug Discovery Summit. Career opportunities: Senior Scientist roles; Postdoctoral GPCR positions. Must-read publications: D2 receptor constitutively active mutants; β2AR allosteric SERS assay; CXCR4 inhibitor burixafor Phase 2. Dr. GPCR University — Reorganized for Clarity and Speed The Dr. GPCR University has undergone a structural redesign. This soft launch prioritizes usability and clarity to support stronger GPCR drug discovery decisions across teams. You can now search courses by level, topic, or instructor. Each course page includes a short trailer, defined learning outcomes, and explicit take-home messages. Full course videos stream directly from the platform, and downloadable resources are available in one place. Legacy courses will migrate into this format over the coming weeks, with live courses returning in March. In the meantime, Premium members continue to have full access to the legacy course pages. Why this matters now: Stop wasting time hunting for relevant training across fragmented platforms. Align your team around structured learning outcomes, not scattered slide decks. Identify the exact knowledge gap slowing your program—and close it efficiently. All courses remain included in Premium Membership. Preview the full University experience ➤ Already a Premium Member? Start learning here ➤ Terry’s Corner — Early Safety Assays For Better GPCR Drug Discovery Decisions Too many discovery programs fail because early safety signals were underestimated—or missed entirely. In this session, Dr. Terry Kenakin walks through the core early assays that protect your chemistry, budget, and timeline. This is not theory. It is operational pharmacology designed to prevent avoidable setbacks. Early safety frameworks directly influence GPCR drug discovery decisions, especially when timelines and capital are tight. What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags. Interpret cytotoxicity data correctly—distinguish transient stress from meaningful off-target damage. Assess hepatotoxicity risk—anticipate reactive metabolites and high-risk drug–drug interactions. Since launch, Terry’s Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics, efficacy, mechanism, ADME, and experimental design. It delivers repeatable depth far beyond a short-format workshop. An upcoming live Ask-Me-Anything (AMA) with Dr. Kenakin takes place February 26 at 12:00 PM EST. Subscribe to the free Kenakin Brief Newsletter to join the AMA . Premium Members get 50%+ discount when they join Terry’s Corner. Access this week’s safety framework ➤ GPCRs: Signal Transduction — Volume II (Call for Papers, Deadline March 14) Signal transduction remains central to understanding GPCR biology across health and disease. A new volume dedicated to GPCR signal transduction invites contributions spanning cellular biochemistry, mechanistic signaling, and translational implications. Submissions are welcome across formats including Original Research, Reviews, Methods, Perspectives, Hypothesis and Theory, Technology and Code, and more. This initiative brings together field experts to advance collective understanding of how GPCR-mediated signaling shapes physiology and pathology. Given the pace of mechanistic and structural insight emerging across the field, coordinated scholarly contribution is timely. Why consider contributing: Position your work within a focused, visible GPCR signaling collection. Contribute to shaping scientific direction in cellular biochemistry. Strengthen field-wide dialogue around signaling mechanisms and dysfunction. Submit your work today ➤ Why Dr. GPCR Premium Membership Gives You an Edge GPCR science is accelerating across obesity, CNS, oncology, and metabolic disease. More data. More companies. More noise. Premium Membership filters that complexity — without filtering out what matters. Each week, you receive curated, signal-focused intelligence: industry developments, classified publications, priority event tracking, curated career opportunities, and full access to Dr. GPCR University courses — now included in Premium. That means structured, searchable, expert-led training across levels and topics — without additional course fees. Premium Members also receive a 50%+ discount on Terry’s Corner , unlocking advanced pharmacology depth and live AMAs with Dr. Terry Kenakin at a significantly reduced cost. This is not commentary. It is structured access and structured education. Premium supports more confident GPCR drug discovery decisions by helping you: Detect meaningful shifts early — without wading through noise. Strengthen mechanistic understanding through organized expert frameworks. Equip your team with repeatable training resources in one place. Reduce external training spend while increasing scientific depth. It supports scientists refining expertise. It strengthens teams executing discovery programs. It equips leaders making strategic and capital decisions. When decisions compound, scattered information creates drag.Structured access creates momentum. Premium delivers that — consistently. Explore Premium Today ➤

Modulator Research Collaboration for Substance Use Disorders "Geneva, Switzerland, August 15, 2022 - Addex Therapeutics

Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic

Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known

Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealized, therapeutic

Phase 1 studies in Japan with JNJ-40411813 (ADX71149) "Geneva, Switzerland, November 15, 2021 – Addex Therapeutics

Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics

Orchestrate the Interface between Health and Disease GPCRs arguably represent the most effective current therapeutic Given the tremendous success of GPCRs as therapeutic targets, considerable focus has been placed on the ability of these therapeutics to modulate diseases by acting at cell surface receptors.

How do molecules make the leap from laboratory concept to therapeutic reality? miss the forest for the trees The critical importance of translation —turning lab data into meaningful therapeutic

diabetes to cancer, fibrosis, and CNS disorders — GPCRs  are at the heart of the world’s most pressing therapeutic Class in Drug Discovery GPCRs regulate countless physiological processes, making them a goldmine for therapeutic But the real  excitement is in what’s next: Biased signaling  for selective therapeutic effects. Orphan GPCRs  with untapped therapeutic potential. you’re in early discovery or clinical development, the strategies here could open doors in your own therapeutic

For innovators building tools, platforms, or therapeutics, these origin moments are where tomorrow’s receptors control localised signaling, how disease hijacks these systems, and how to target them for therapeutic Her work sits at the intersection of fundamental biology and therapeutic strategy. Knowing where  signals occur could unlock new therapeutic strategies, better efficacy, and fewer side

signaling, influencing a wide array of physiological processes and serving as critical targets for therapeutic significant findings that enhance our understanding of GPCRs' roles in immune function and potential therapeutic macrophages suggest that these GPCRs could be targeted to modulate inflammatory responses, offering potential therapeutic the field continues to evolve, the insights gained from this research will be instrumental in shaping therapeutic

This foundational knowledge guides researchers in the development of new therapeutics. It can inform decisions in drug design, improving therapeutic outcomes and reducing unwanted side effects This understanding can enhance your appreciation for drug development and therapeutic action.

and the complexity of the central nervous system (CNS) pose a challenge for developing successful therapeutics Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Of the traditional GPCRs, CBRs are gaining ground as potential therapeutic targets in several CNS diseases One of the best tools to study therapeutic targets are fluorescent ligands , which are very useful in G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative

Selection  – Master GPCR behavior beyond second messengers   Build sharper strategies for GPCR-targeted therapeutics receptor biology—and how they’re being used to de-orphanize GPCRs, explore autoantibodies, and uncover new therapeutic

mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics Biased signalling of Class B G protein-coupled receptor-targeted therapeutics .  

Our partner, Domain Therapeutics, will attend the SACHS 23rd annual biotech event in Europe. Dr. Christopher Langmead and colleagues' work on the 5-HT2C receptor as a therapeutic target for substance GPCR Symposium on ''GPCRs as Therapeutic Modalities' Share your project with a 1-minute abstract video Protein and Exendin-P5 Biased Agonist Molecular and structural insights into the 5-HT2C receptor as a therapeutic teams up with addiction treatment maker Indivior to make digital therapeutics for substance use disorders

for Drug Discovery DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Tectonic Therapeutic Announces

Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

November 7th : Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th : Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with SEP-786, a Novel Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism Confo Therapeutics a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety OMass Therapeutics

This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics acids conjugation with [Cp*Rh(H2O)3]2+ by using the meta-dynamics/FMO3 approach Industry News GPCR Therapeutics - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Study Neurocrine opening two Phase 1 trials in oral Parkinson’s therapies Bearing Fruit: Deep Apple Therapeutics Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative

This approach reveals: Hidden target overlap New therapeutic hypotheses “Off-target” effects that may This reroutes discovery toward: Functionally selective ligands Better therapeutic windows More predictable What matters now is not the category , but the fit: Does the chemical matter support the therapeutic